Diclofenac sodium, also known as Voltaren, is a non-steroidal anti-inflammatory drug (NSAID) that has been used for over four decades to treat various forms of pain and inflammation. As a pharmaceutical raw material, diclofenac sodium is a crucial component of many drugs used for treating arthritis, osteoarthritis, ankylosing spondylitis, menstrual cramps, and other types of pain caused by inflammation.
HEBEI SINOAH PHARM-TECH CO., LTD is a Chinese company that specializes in producing and marketing pharmaceutical raw materials. They are known for their excellent quality products, including diclofenac sodium.
Diclofenac sodium is known for its remarkable effectiveness in reducing pain and inflammation. It works by reducing the production of prostaglandins which are responsible for inflammation, swelling, and pain. Besides being an effective painkiller, diclofenac sodium is also known for its quick action. It is absorbed by the body within a few minutes of ingestion and starts working within 30 minutes.
Diclofenac sodium is available in different formulations, including tablets, creams, gels, and injections, enabling doctors to prescribe different forms based on individual patient needs. A study published in The Lancet in 2018 showed that diclofenac sodium is one of the most effective and safe NSAIDs in the treatment of pain and inflammation. The study compared 21 different NSAIDs and concluded that diclofenac sodium was among the most effective.
Diclofenac potassium is also a popular component in the production of many anti-inflammatory drugs. It has the same effects as diclofenac sodium but is mainly used for reducing pain associated with soft tissue injuries such as sprains and strains.
TECSUN PHARMA LIMITED, which is linked to the company that produces diclofenac sodium, is a joint-stock company that specializes in producing and marketing pharmaceutical products, including APIs, human, and veterinary drugs, finished products of veterinary drugs, feed additives, and amino acids. The company has achieved several milestones since its inception in 2005, with a focus on producing high-quality pharmaceutical products that meet international standards.
The use of diclofenac sodium as a pharmaceutical raw material is on the rise worldwide and the demand for it is set to increase in the coming years. Several factors are driving this growth, including an aging population, increased awareness and access to healthcare, and an increase in chronic diseases that cause pain and inflammation.
As more people discover the effectiveness of diclofenac sodium, pharmaceutical companies are branching out to produce a range of products using the ingredient. The growth potential for companies such as HEBEI SINOAH PHARM-TECH CO., LTD and TECSUN PHARMA LIMITED is significant, with a ready market for high-quality pharmaceutical raw materials such as diclofenac sodium.
In conclusion, diclofenac sodium is a crucial component in the production of many drugs used for treating pain and inflammation. Its effectiveness and quick action make it a popular choice among doctors and patients alike. Companies such as HEBEI SINOAH PHARM-TECH CO., LTD and TECSUN PHARMA LIMITED are at the forefront of producing high-quality pharmaceutical raw materials, including diclofenac sodium, to meet the increasing demand for effective and safe pain relief.